HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?

Steven A. Smith

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

HbA1c is currently the best clinical measure of assessing the degree of glycemic exposure for patients with diabetes. Epidemiologic, observational, and clinical trials have found a consistent relationship between HbA1c, improved glycemic control, and the microvascular risks of diabetes, while there remains an uncertainty about the risk-benefits of aggressive glycemic control and macrovascular events. HbA1c as a measure of glycemic control is an important but not the only therapeutic target in the outpatient management of diabetes. Diabetes management requires the collective attention to other proximate outcomes; biomarkers (e.g., lipids, blood pressure, and weight) and behavioral measures (e.g., knowledge, adherence, trust) that predict patient important outcomes of morbidity, mortality, and quality of life.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Diabetes
PublisherWiley-Blackwell
Pages96-104
Number of pages9
ISBN (Print)9781405169288
DOIs
StatePublished - Mar 31 2011

Keywords

  • CGMS
  • HbA1c
  • HemoglobinA1c
  • Macrovascular
  • Microvascular
  • Outcomes
  • Risk

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?'. Together they form a unique fingerprint.

  • Cite this